RFL - Rafael Pharma's devimistat fast track'd in U.S. for acute myeloid leukemia

The FDA has designated Fast Track status to Rafael Pharmaceuticals' ([[RFL]] +0.3%) to its lead compound, CPI-613 (devimistat), for the treatment of acute myeloid leukemia.This announcement comes on the heels of the Company receiving Fast Track designation for devimistat for the treatment of metastatic pancreatic cancer, in November, as well as recent FDA Orphan Drug tag for the treatment of soft tissue sarcoma for devimistat.Also this month initiated a Phase 2 trial of devimistat in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue.

For further details see:

Rafael Pharma's devimistat fast track'd in U.S. for acute myeloid leukemia